Why hasn't eliminating acute rejection improved graft survival?

被引:76
作者
Tantravahi, JogiRaju [1 ]
Womer, Karl L.
Kaplan, Bruce
机构
[1] Univ Florida, Coll Med, Div Nephrol Hypertens & Renal Transplantat, Gainesville, FL 32601 USA
[2] Malcom Randall VA Med Ctr, Gainesville, FL 32610 USA
[3] Univ Illinois, Transplant Ctr, Dept Med, Coll Med, Chicago, IL 60612 USA
来源
ANNUAL REVIEW OF MEDICINE | 2007年 / 58卷
关键词
kidney transplantation; allograft survival; donor and recipient factors; calcineurin inhibitor toxicity; chronic allograft nephropathy; BK virus nephropathy;
D O I
10.1146/annurev.med.58.061705.145143
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although patients with end-stage renal disease can be maintained with dialysis therapy, the superiority of patient survival with renal transplantation makes transplantation the preferred method of renal replacement. Potent immunosuppressive therapies, particularly calcineurin inhibitors, have greatly reduced the incidence of acute rejection. However, long-term allograft survival remains limited. We discuss the impact of acute rejection on long-term allograft survival and discuss other factors leading to late allograft loss, including calcineurin inhibitor toxicity, chronic allograft nephropathy, and BK virus nephropathy, as well as donor and recipient factors associated with long-term allograft loss.
引用
收藏
页码:369 / 385
页数:17
相关论文
共 71 条
[1]   Dual-kidney transplants: Long-term results [J].
Alfrey, EJ ;
Boissy, AR ;
Lerner, SM .
TRANSPLANTATION, 2003, 75 (08) :1232-1236
[2]   Long-term trends in allograft survival [J].
Brennan, DC .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2006, 13 (01) :11-17
[3]   Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction [J].
Brennan, DC ;
Agha, I ;
Bohl, DL ;
Schnitzler, MA ;
Hardinger, HL ;
Lockwood, M ;
Torrence, S ;
Schuessler, R ;
Roby, T ;
Gaudreault-Keener, M ;
Storch, GA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :582-594
[4]   Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients [J].
Ciancio, G ;
Burke, GW ;
Suzart, K ;
Roth, D ;
Kupin, W ;
Rosen, A ;
Olson, L ;
Esquenazi, V ;
Miller, J .
TRANSPLANTATION, 2002, 73 (07) :1100-1106
[5]   Kidney and pancreas transplantation in the United States, 1995-2004 [J].
Cohen, DJ ;
St Martin, L ;
Christensen, LL ;
Bloom, RD ;
Sung, RS .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) :1153-1169
[6]   Living-donor kidney transplantation: A review of the current practices for the live donor [J].
Davis, CL ;
Delmonico, FL .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2098-2110
[7]   Immunosuppressive strategies in transplantation [J].
Denton, MD ;
Magee, CC ;
Sayegh, MH .
LANCET, 1999, 353 (9158) :1083-1091
[8]   BK-VIRUS INFECTION IN PATIENTS WITH AIDS [J].
FLAEGSTAD, T ;
PERMIN, H ;
HUSEBEKK, A ;
HUSBY, G ;
TRAAVIK, T .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1988, 20 (02) :145-150
[9]   The stability of the glomerular filtration rate after renal transplantation is improving [J].
Gourishankar, S ;
Hunsicker, LG ;
Jhangri, GS ;
Cockfield, SM ;
Halloran, PF .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :2387-2394
[10]   Improved graft survival after renal transplantation in the United States, 1988 to 1996. [J].
Hariharan, S ;
Johnson, CP ;
Bresnahan, BA ;
Taranto, SE ;
McIntosh, MJ ;
Stablein, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :605-612